Tests daraxonrasib against docetaxel in previously treated lung cancer with RAS mutations
Compares daraxonrasib with docetaxel in adults with previously treated RAS-mutated lung cancer.
Plain-language title generated from the registry record
Registry title: Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Key facts
- Where
- Blacktown, Camperdown, Kogarah, Melbourne, Perth, South Brisbane, and Waratah, AustraliaSee the 7 sites
- Phase
- Phase 3
Where in Australia
- Blacktown Medical Oncology Research, Blacktown HospitalBlacktown, AustraliaNo longer taking part
- Chris O'Brien LifehouseCamperdown, AustraliaNo longer taking part
- St. George Private Hospital Clinical Trials UnitKogarah, AustraliaNo longer taking part
- Alfred HouseMelbourne, AustraliaNo longer taking part
- Sir Charles Gairdner HospitalPerth, AustraliaNo longer taking part
- Mater Misericordiae LimitedSouth Brisbane, AustraliaNo longer taking part
- Calvary Mater NewcastleWaratah, AustraliaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Revolution Medicines, Inc.
- Trial code
- NCT06881784EU 2024-518154-16-00
- Record updated
- 6 November 2026
- Original description
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.Read full original descriptionShow less
RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 Versus Docetaxel in Patients With Previously Treated Locally Advanced or Metastatic RAS[MUT] NSCLC
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Inclusion: At least 18 years old and has provided informed consent; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; Pathologically confirmed NSCLC, either locally advanced or metastatic, not amenable to curative surgery or radiotherapy; Measurable disease per RECIST v1.1; Adequate organ function (bone marrow, liver, kidney, coagulation); One to two prior lines of therapy including an anti-PD-1/anti-PD(L)-1 agent and platinum-based chemotherapy; Documented RAS mutation status, defined as Nonsynonymous mutations in KRAS, NRAS, or HRAS at codons 12, 13, or 61 (G12, G13, or Q61); Able to take oral medications.
Exclusion: Prior therapy with direct RAS-targeted therapy or docetaxel; Ongoing anticancer therapy; Medically significant comorbidities (significant cardiovascular disease, lung disease, or impaired GI function); Untreated central nervous system (CNS) metastases; Pregnant or breastfeeding.